• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-Deoxy-D-Glucose (2DG)
      • Acacia Cyanophylla Flower
      • Acori Graminei Rhizoma
      • Aegle Marmelos Correa
      • Agaricus Blazei
      • Aged Garlic Extract
      • Aframomum Melegueta
      • Aloe Arborescens
      • Albizia
      • Alpinia Officinarum
      • Alternanthera Sessilis
      • American Ginseng
      • Amygdalin
      • Anacyclus Pyrethrum
      • Angelica Archangelica
      • Angelica Sinensis
      • Antrodia
      • Artichoke Leaf
      • Artocarpin
      • Ajuga Turkestanica
      • Ashwagandha
      • Aspalathin
      • Astragalus Complanatus
      • Avena Sativa
      • Bacopa Monnieri
      • Bavachin
      • Bee Pollen
      • Betulinic Acid
      • Boswellic Acid
      • Brevilin A
      • Campesterol
      • Casticin
      • Chrysin
      • Cinnamomum Zeylanicum
      • Citrullus Colocynthis
      • Citrus Reticulata Peel
      • Codonopsis
      • Costunolide
      • Cucurbitacin D
      • Daidzein
      • Decursin
      • Delphinidin
      • Digitalis Purprea (Digoxin)
      • Diosmin
      • Embelin
      • Gallic Acid
      • Glycitein
      • Glycyrrhizin
      • Hyperforin
      • Icariin
      • Isorhamnetin
      • Isoorientin
      • Isovitexin
      • Jaceosidin
      • Kaempferol
      • Kurarinone
      • Lemon balm
      • Licoricidin
      • Lipoic acid
      • Lupeol
      • Magnolol
      • Mulberry Leaf
      • Naringenin
      • Nobiletin
      • Oleacein
      • Oleanolic acid
      • Oridonin
      • Parthenolide
      • Phloroglucinol
      • Piceatannol
      • Pristimerin
      • Proanthocyanidins
      • Procyanidin B3
      • Pseudolaric acid b
      • Pterostilbene
      • Rutin
      • Solidago Virgaurea
      • Tangeretin
      • Taraxasterol
      • Trichostatin A
      • Wedelolactone
      • Wogonin
      • Yerba Mate
    • ABOUT
    • SCIENTIFIC STUDIES
      • ALLERGIES & CYTOKINES
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • AMPK
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • APOPTOSIS
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • CARDIAC GLYCOSIDES
      • CENTENARIANS
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • EPIGENETIC MODIFIERS
      • FGF21
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HMGB1
      • HSP90 INHIBITORS
      • HYPERINSULINEMIA
      • IKK
      • IL-6/STAT3
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INSULIN & AGING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LIFESPAN EXTENSION
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MSG (MONOSOSODIUM GLUTAMATE)
      • mTOR: THE RAPID AGING PATHWAY
      • NEUROINFLAMMATION
      • NMDA & ANXIETY & DEPRESSION
      • NOOTROPICS
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PPARY2
      • PREMATURE SENESCENCE
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SIRT1 & LONGEVITY
      • SUGAR & AGING
      • STAT3
      • TELOMERE SHORTENING & PREMATURE AGING
    • HOME
    • FAQ
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
    January 22, 2020
    P38MAPK
    January 23, 2020

    Advanced glycation end products

    Key players in skin aging?

    Abstract

    Aging is the progressive accumulation of damage to an organism over time leading to disease and death. Aging research has been very intensive in the last years aiming at characterizing the pathophysiology of aging and finding possibilities to fight age-related diseases. Various theories of aging have been proposed. In the last years advanced glycation end products (AGEs) have received particular attention in this context. AGEs are formed in high amounts in diabetes but also in the physiological organism during aging. They have been etiologically implicated in numerous diabetes- and age-related diseases. Strategies inhibiting AGE accumulation and signaling seem to possess a therapeutic potential in these pathologies. However, still little is known on the precise role of AGEs during skin aging. In this review the existing literature on AGEs and skin aging will be reviewed. In addition, existing and potential anti-AGE strategies that may be beneficial on skin aging will be discussed.

    Keywords: : advanced glycation end products, skin aging, photoaging, RAGE, AGEs

    Introduction

    Aging is defined as the progressive accumulation of damage over time, leading to disturbed function on the cellular, tissue and organ level and eventually to disease and death. Aging is a complex, multifactorial process where genetic, endogenous and environmental factors play a role.1

    Skin is the largest organ of the human body and also the boundary between an organism and environment. As such, skin is subjected not only to the internal aging process but also to various external stressors, leading to distinct structural changes and affecting not only its youthful appearance, but also its various physiological functions. Aged skin shows disturbed skin permeability, angiogenesis, lipid and sweat production, immune function and vitamin D synthesis, manifesting among others as impaired wound healing, atrophy, vulnerability to external stimuli and development of several benign and malignant diseases (reviewed in Zouboulis et al.).2

    Endogenously aged skin refers to changes reflecting the internal aging process of the organism and is being observed mainly in ultraviolet (UV) light-protected skin areas, such as the inner side of the arms. Macroscopically it is recognized by fine wrinkles, loss of elasticity, reduced epidermal and dermal thickness, while microscopically epidermal atrophy, decreased mitotic rate of basal keratinocytes, decreased proliferative capacity and cellular senescence, atrophy of the dermal extracellular matrix and change of the physiological properties of the connective tissue are typical characteristics.2–4 Exogenously aged skin or photoaged skin is the skin where endogenous aging processes are being aggravated by external stressors, mainly UV irradiation,2,5 but also by tobacco,6 chemicals and pollution.2,4 Apart from many similarities with endogenously aged skin, extrinsic aged skin is also characterized by a thickened epidermis and a hyperplasia of elastic tissue (solar elastosis).2,4

    Until today, more than 300 theories of aging have been proposed, among them the theory of cellular senescence, decreased proliferative capacity and telomere shortening, mitochondrial DNA single mutations, the free radical theory and others, none of which can fully explain all changes observed in aging.7–11 According to the inflammatory theory of aging, a common characteristic of skin aging factors is their ability to induce or maintain proinflammatory changes and trigger a local inflammatory response which through subsequent immune responses, matrix metalloproteinase (MMP) activation and proinflammatory cytokine production contributes to the structural changes observed in aged skin.12

    In the recent years, the role of advanced glycation end products (AGEs) has been increasingly discussed in skin aging, and the potential of anti-AGE strategies has received high interest from pharmaceutical companies for the development of novel anti-aging cosmeceutical compounds.

    The aim of this work is to critically review the existing literature on AGEs and provide evidence that they play an important role in the pathogenesis of skin aging. Furthermore, existing and potential strategies against the deleterious effects of AGEs on skin aging will be discussed.

    Biochemistry of AGEs

    Glycation is the non-enzymatic reaction between reducing sugars, such as glucose, and proteins, lipids or nucleic acids.13 Glycation has to be distinguished from glycosylation, which is an enzymatic reaction. Since its first description by Maillard in 1912 and its involvement in food browning during thermal processing by Hodge 50 years later, its presence in living systems and involvement in various pathologies of the human body, including aging and diabetes, have been an intensive field of research.14,15

    Formation of AGEs is a complicated molecular process involving simple and more complex multistep reactions. During the classical Maillard reaction electrophilic carbonyl groups of glucose or other reactive sugars react with free amino groups of amino acids (especially of basic lysine or arginine residues), forming a non-stable Schiff base.16 Further rearrangement leads to formation of a more stable ketoamine (Amadori product) (Fig. 1).13,16 Schiff bases and Amadori products are reversible reaction products. However, they can react irreversibly with amino acid residues of peptides or proteins to form protein adducts or protein crosslinks.13,16 Alternatively, they can undergo further oxidation, dehydration, polymerization and oxidative breakdown reactions to give rise to numerous other AGEs.13,17 Oxygen, reactive oxygen species (ROS) and redox active transition metals accelerate AGE formation. When an oxidative step is involved, the products are called advanced glycoxidation end products.13,17

    Figure 1. Schematic presentation of the Maillard reaction. Reactive carbonyl groups of a reducing sugar react with neutrophilic free amino groups of proteins to form a reversible Schiff base. Through rearrangement a more stable Amadori product is formed. Dependent on the nature of these early glycation end products, protein adducts or protein crosslinks are formed.

    Display full size

    AGEs are a very heterogeneous group of molecules. Since the discovery of the first glycated protein, glycated hemoglobin in diabetes, numerous other AGEs have been detected. Some of them have characteristic autofluorescent properties, which simplifies their identification in situ or in vivo.13 To date, numerous AGEs have been identified. Table 1 lists the most commonly found ones in the skin.17–28

    Table 1. Detected AGEs in skin*

    CSVDisplay Table

    Carboxymethyl-lysine (CML) was first described by Ahmed and represents the most prevalent AGE in vivo.29,30 It is a non-fluorescent protein adduct. Mechanisms of its formation include oxidative degradation of Amadori products or direct addition of glyoxal to lysine. It seems to be the major epitope of the commonly used polyclonal anti-AGE antibodies.30

    Pentosidine was first isolated and characterized by Sell and Monnier. It is composed of an arginine and a lysine residue crosslinked to a pentose.31 Pentosidine is a fluorescent glycoxidation product and forms protein-protein crosslinks.16

    Dicarbonyl compounds like 3-deoxyglucosome, methylglyoxal and glyoxal derive from oxidative degradation or autooxidation of Amadori products and other pathways.13,32 These dicarbonyl compounds are very reactive molecules leading to protein crosslinks.13 Other in vivo characterized AGEs include glucosepane, carboxymethyl-hydroxy-lysine, carboxyethyl-lysine (CEL), fructose-lysine, methylglyoxal-derived hydroimidazolones and pyrraline, which form non-fluorescent protein adducts, while glyoxal-lysine dimer (GOLD) and methylglyoxal-lysine dimer (MOLD) form non-fluorescent protein crosslinks.13,17

    AGEs can be exogenously ingested (through food consumption) or be endogenously produced. Endogenous AGE formation is increased in diabetes; however, AGEs are also formed at lower rates by normal metabolic processes of the organism.33 Environmental factors, such as diet and smoking influence the rate of AGE formation.34 Moreover, it seems that the level of circulating AGEs levels are genetically determined, as shown in a cohort study of healthy monozygotic and heterozygotic twins.35

    The content of AGEs in the organism is not only defined by the rate of their formation but also by the rate of their removal. Many cells have developed intrinsic detoxifying pathways against accumulation of AGEs.36 The glutathione-dependent glyoxalase system, comprising of glyoxalase (Glo) I and II, has a key role in the defense against glycation.37 This system uses reduced glutathione (GSH) to catalyze the conversion of glyoxal, methylglyoxal and other α-oxoaldehydes to the less toxic D-lactate.37 Other enzymatic systems include fructosyl-amine oxidases (FAOXs) and fructosamine kinases, relatively new classes of enzymes which recognize and break Amadori products.38 However, FAOXs or “amadoriases” have been found to be expressed only in bacteria, yeast and fungi but not in mammals. They oxidatively break Amadori products but act mostly on low molecular weight compounds.39 On the contrary, fructosamine kinases are expressed in various genomes including humans.38 These intracellular enzymes phosphorylate and destabilize Amadori products leading to their spontaneous breakdown.39Fructosamine-3-kinase (FN3K), one of the most studied enzymes in this system, is almost ubiquitary expressed in human tissues including the skin. Thus, it plays an important role in the intracellular breakdown of Amadori products.40

    Receptors for AGEs

    AGEs not only exert their deleterious actions due to their biological properties per se, but also through their interaction with specific receptors. Receptor for AGEs (RAGE) is a multiligand member of the immunoglobulin superfamily of cell surface receptors, encoded by a gene on chromosome 6 near the major histocompatibility complex III. It is a pattern recognition receptor binding in addition to AGEs various other molecules such as S-100/calgranulins, high motility group protein B1 (amphoterine), β-amyloid peptides and β-sheet fibrils.33,41 The binding of ligands to RAGE stimulates various signaling pathways including the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinases (ERK) 1 and 2, phosphatidyl-inositol 3 kinase, p21Ras, stress-activated protein kinase/c-Jun-N-terminal kinase and the janus kinases.33,41 Stimulation of RAGE results in activation of the transcription factor nuclear factor kappa-B (NFκB) and subsequent transcription of many proinflammatory genes.41,42Interestingly, RAGE-induced activation of NFκB is characterized by a sustained and self-perpetuating action, through induction of positive feedback loops and overwhelming of the autoregulatory negative feedback loops. RAGE activation leads to new synthesis of the transcriptionally active subunit p65, which overwhelms the newly synthesized inhibitor IκBα. Moreover NFκB increases further expression of RAGE, which itself further stimulates NFκB, forming a vicious cycle of self-renewing and perpetuating proinflammatory signals.41 RAGE activation can directly induce oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX), decreasing activity of superoxide dismutase (SOD), catalase and other pathways, and indirectly by reducing cellular antioxidant defenses, like GSH and ascorbic acid.41,43,44 The reduction of GSH leads furthermore to decreased activity of Glo I, the major cellular defense system against methylglyoxal, therefore supporting further production of AGEs.37 RAGE is almost ubiquitary expressed in the organism, typically at low levels, and its expression is upregulated under various pathologic conditions.41,45 In the skin, RAGE expression was observed in both epidermis and dermis, and it was increased in sun-exposed compared with UV irradiation-protected areas. Keratinocytes, fibroblasts, dendritic cells and to a lesser extent endothelial cells and lymphocytes express RAGE.45 Not only in vivo, but also in vitro, various skin cells types have been shown to express RAGE (Table 2).43,45–51

    Table 2. Expression of human RAGE in skin and skin cells*

    CSVDisplay Table

    RAGE is the most studied receptor for advanced glycation end products. Another group of cell surface receptors, AGER1, AGER2 and AGER3 seem to regulate endocytosis and degradation of AGEs, thus counteracting the effects of RAGE.52 AGER1 has been further shown to counteract AGEs-induced oxidative stress via inhibition of RAGE signaling.53,54 Soluble RAGE (sRAGE) is a truncated splice variant of RAGE containing the ligand-binding domain but not the transmembrane domain and has been found in plasma. sRAGE is a soluble extracellular protein without signaling properties and it is considered as a natural decoy receptor of RAGE.55

    Role of AGEs During Skin Aging

    Cutaneous accumulation of AGEs is a feature of skin aging

    As mentioned above, AGEs can be directly formed in the organism or be exogenously ingested. Accumulation of AGEs has been detected in various tissues during aging and diabetes, including articular collagen, skeletal and smooth vascular muscles or glomerular basement membranes.56–58 Accordingly, deposited AGEs in these tissues have been implicated in various diabetes- or age-associated pathologies such as diabetic angiopathy, age- and diabetes-associated macular degeneration and osteoarthritis.56–62

    Skin, due to its easy accessibility, offers an excellent opportunity for minimal invasive or even non-invasive investigation of glycation, taking advantage of the characteristic autofluorescent properties of AGEs. Accumulation of AGEs in the skin has been therefore thoroughly studied and is detected not only in diabetes as expected but also during chronological aging.20,63,64 Glycation-associated skin autofluorescence was shown to correlate with chronological aging in a large number of healthy subjects.65

    It is a general perception today that AGE accumulation is dependent on protein turnover rate; therefore long-lived proteins are thought to be mainly modified by glycation.66 Collagen types I and IV, exhibiting a slow turnover rate of about 10 y, and other dermal long-lived proteins like fibronectin mainly suffer from glycation during intrinsic chronological aging.19,20 The appearance of glycated collagen is first observed at the age of 20. It accumulates with a yearly rate of about 3,7% reaching a 30–50% increase at 80 y of age.20,67 CML was recently histochemically detected in human epidermis from healthy donors.18 The upper epidermal layers were mostly involved (stratum spinosum, granulosum and corneum) and the authors identified cytokeratin 10 (CK10) (expressed by differentiated keratinocytes) as a target protein for CML modification. The amount of CML in younger donors seemed to be weak in comparison to the older ones. The latter study had restrictions, as the size of the sample was small and heterogeneous, but indicates a potential involvement of AGEs in epidermal physiology and a possible involvement of more short-lived proteins in glycation chemistry. Moreover, in an in vitro reconstructed organ skin model, both epidermis and dermis, as well as their functions, were modified by glycation.68

    AGEs also seem to highly accumulate in extrinsically aged skin. Until now, the deleterious effects of UV irradiation have been mainly attributed to proinflammatory changes, apoptosis, oxidative damage, mutagenesis and induction of MMPs.2,5 However, it has been shown that in young individuals, where typically no significant accumulation of AGEs in sun-protected skin is observed, sun-exposed areas display an increased deposition of these substances.20,69 Accumulation of AGEs was mainly found in sites of solar elastosis in sun-exposed skin, showing that UV irradiation may also precipitate the formation of AGEs in vivo.20,23 It is tempting to speculate that formation of AGEs in sun-exposed skin may be one additional mechanism mediating the various structural and functional modifications during photoaging.

    Moreover, smoking, a typical aggravating factor of skin aging, accelerates formation of AGEs and increases their deposition in various tissues including skin.70,71 Another important environmental factor for aging is diet. The content of AGEs in food is highly dependent on the method of preparation, like cooking time and temperature. Fried food contains in general far higher amounts of AGEs than boiled or steamed food.72 Approximately 10–30% of ingested AGEs are absorbed in the circulation.73 Dietary AGEs directly correlate with serum levels of AGEs and inflammatory markers in healthy human subjects, respectively.73

    It has been widely accepted that AGEs, once formed, can be only removed when the modified proteins degrade. However it has now become apparent that in the organism various enzymatic systems seem to be involved in the degradation or removal of AGEs. As mentioned above, Glo I is an enzyme responsible for the removal of reactive α-dicarbonyl compounds. Interestingly, decreased activity of such defense systems against AGEs has been reported during aging.44 These age-related changes may further increase the extent of deposited AGEs in a living organism over time.

    Consequences of AGE deposition in skin

    AGEs can be formed intracellularly and extracellularly. Their presence in biological molecules modifies their biomechanical and functional properties. Proteins, lipids and nucleic acids can be targets of advanced glycation, modifying enzyme-substrate interactions, protein-DNA interactions, protein-protein interactions, DNA regulation and epigenetic modulation, thus interfering with numerous physiological functions of the organism. Moreover, AGEs are themselves reactive molecules which through interaction with their receptors activate various molecular pathways in vivo, thus becoming involved in inflammation, immune response, cell proliferation and gene expression (Fig. 2).

    Figure 2. Effects of AGEs on skin. AGEs are formed intracellularly and extracellularly. They can react with proteins, lipids and nucleic acids in almost all skin cells as well as on intracellular or extracellular proteins. Through alteration of the physicochemical properties of dermal proteins, decreased cell proliferation, increased apoptosis and senescence, induction of oxidative stress and proinflammatory mediators as well as other pathways, AGEs contribute to the overall picture of skin aging. Triangles represent AGEs. Abbreviations: jak/stat, januskinase/signal transducers and activators of transcription; MCP-1, monocyte chemotactic protein-1; all other abbreviations are already explained in the text.

    Display full size

    1. Extracellular matrix proteins

    Extracellular matrix (ECM) proteins have been regarded as one of the major target structures for glycation. The most abundant collagen type in the skin is type I, whereas collagen IV is being found in the basal membrane. Collagen is one of the strongest proteins. In the skin, it is not only used as a supportive framework for mechanical support for cells and tissues, but represents an active component being able to interact with cells and affect various cellular functions such as migration, differentiation and proliferation.

    Collagen glycation impairs its function in various ways. Intermolecular crosslinks of adjacent collagen fibers change its biomechanical properties leading to stiffness and decreased flexibility, thus increasing its susceptibility to mechanical stimuli.74 The change of its charge and the formation of AGEs on side chains of collagen affect its contact sites with cells and other matrix proteins and inhibit its ability to react with them.75 The precise aggregation of monomers into the triple helix may be affected as well as the association of collagen IV with laminin in the basal membrane.16 Modified collagen resists degradation by MMPs, thus inhibiting its removal and replacement by newly synthesized and functional one.62Accordingly, tissue permeability and turnover is impaired.16,76

    Other extracellular matrix proteins suffering from advanced glycation are elastin and fibronectin, contributing further to dermal dysfunction.19,20,23 Of note, CML-modified elastin has been found almost exclusively in sites of actinic elastosis and not in sun-protected skin, underlining its potential role in photoaging. Indeed, UV irradiation stimulates glycation of elastin in the presence of sugars. Moreover, CML-modified elastin assembled in large and irregular structures, has decreased elasticity and is resistant to proteolytic degradation.77

    It has been shown that in vitro glycated skin samples have impaired biomechanical properties.78 In vivo, decreased skin elasticity characterizes diabetic subjects in comparison to healthy controls.79

    2. Intracellular proteins

    Intermediate filaments such as vimentin in fibroblasts and CK10 in keratinocytes have been found to be modified by AGEs.18,22 Cytoskeletal proteins are important in providing stability of the cytoskeleton and are crucially involved in numerous cellular functions such as migration and cellular division. Various other intracellular proteins including enzymes and growth factors may be targets of non-enzymatic modification by sugars. Glycated basic fibroblast growth factor (bFGF) displays impaired mitogenic activity in endothelial cells.80 Glycation of enzymes of the ubiquitin-proteasome system and of the lysosomal proteolytic system has been shown to inhibit their action.81 Antioxidant and other protective enzymes such as Cu-Zn-SOD can be inactivated.82 Other intracellular components, such as DNA and lipids can be glycated with detrimental effects on their function.13,83

    3. Receptors for AGEs: RAGE

    AGEs do not only act by altering the physicochemical properties of glycated proteins. Interestingly, AGEs may bind to their cell surface receptor, RAGE, initiating a cascade of signals influencing cell cycle and proliferation, gene expression, inflammation and extracellular matrix synthesis (reviewed in Bierhaus et al.).41 As mentioned above, RAGE is broadly expressed in human skin and in epidermal keratinocytes, dermal fibroblasts and endothelial cells in vitro. It is highly found in sites of solar elastosis, and its expression is induced by advanced glycation end products and proinflammatory cytokines like TNFα.45 In skin cells RAGE has been shown to decrease cell proliferation, induce apoptosis and increase MMPs production.47 Many of these effects involve NFκB signaling.47

    4. Effects of AGEs on resident skin cells

    AGEs have been shown to affect various functions of skin cells in vitro (Table 3). They decrease proliferation and enhance apoptosis of human dermal fibroblasts, an effect which is at least partly RAGE-dependent and correlates with the activation of NFκB and caspases.87 In keratinocytes, AGEs decrease cell viability and migration and induce the expression of proinflammatory mediators.84 Moreover, AGEs are able to induce premature senescence in human dermal fibroblasts and in normal human keratinocytes in vitro.86,89,90 Collagen and ECM protein synthesis have been also found to be decreased, while the expression of MMPs is induced.47 Dicarbonyls such as glyoxal and methylglyoxal impair the signaling of epidermal growth factor receptor (EGFR), a receptor controlling various cellular functions such as proliferation, differentiation, motility and survival, by formation of EGFR crosslinks, blocking of phosphorylation and impaired activation of ERKs and phospholipase C.92 Various other growth factors or proteins significant for cellular functions, like bFGF, may be glycated inhibiting their functions.80 In the context of extrinsic aging, AGEs seem to render cells more sensitive to external stimuli, as UVA irradiated fibroblasts and keratinocytes exhibit decreased viability after exposure to AGEs.85,93

    Table 3. Effects of AGEs/RAGE on skin morphology and physiology during aging*

    CSVDisplay Table

    5. The role of oxidative stress

    Oxidative stress has been widely accepted to mediate the deleterious effects of solar radiation in the skin during photoaging. Interestingly, in vitro exposure of AGEs to UVA irradiation leads to formation of ROS, such as superoxide anion, hydrogen peroxide and hydroxyl radicals.93 AGEs can lead to ROS formation in cells by various ways. They can stimulate NOX to induce production of superoxide anion or they can compromise cellular antioxidant defense systems, e.g. inactivation of Cu-Zn-SOD by cross-linking and site-specific fragmentation of this molecule.82 Moreover, AGEs are themselves very reactive molecules. As early as during their crosslinking reactions they can act as electron donors leading to formation of superoxide anions.94 Glycation of proteins creates active enzyme-like centers (cation-radical sites of crosslinked proteins) able to catalyze one-electron oxidation-reduction reactions leading to ROS generation with or without presence of oxygen or transition metals such as iron and copper.94-,96

    Finally, autofluorescent AGEs, such as pentosidine, can act as endogenous photosensitizers leading to increased ROS formation after UVA irradiation of human skin.97 UV irradiation of human keratinocytes and fibroblasts in the presence of AGEs led to increased ROS formation and decreased proliferation in vitro.85

    6. Skin AGEs as biomarkers of aging

    As AGEs have been etiologically implicated in aging and aging-related pathologies, the idea of using them as biomarkers is appealing. AGEs in the skin have been initially measured by western blots (WB) with polyclonal antibodies or by autofluorescence measurements of skin biopsies, thus restricting the wide use of these measurements. An AGE-Reader (DiagnOptics B.V., Groningen, The Netherlands) has been introduced some years ago as a new, non-invasive method to measure in vivo the skin content of AGEs based on their characteristic autofluorescence.98–100

    Until now it has been shown that skin autofluorescence positively correlates with various diabetes- and age-related complications such as micro- and macrovascular complications, renal disease, cardiovascular events, overall mortality, age-related macular degeneration and chronic renal disease.99,101,102 Skin glycation has been proposed as a prognostic factor for the development of diabetic complications.103Lately it was shown that skin autofluorescence increases with chronological aging and correlates with skin deposition of AGEs, making this method a potential tool in investigating the effect of various anti-aging products of the cosmetic industry.104

    Anti-AGE Strategies: Current Knowledge and Future Perspectives

    Since the emergence of AGEs as an important pathogenetic factor in diabetes and aging the development of strategies against AGEs has been in the center of scientific interest. Substances able to prevent or inhibit formation of AGEs, as well as agents able to break already formed AGEs or those antagonizing their signaling have been identified. Some of them are already being tested in clinical trials.105,106

    1. Substances preventing or inhibiting AGE formation

    Aminoguanidine was one of the first substances identified limiting the formation of AGEs.107Aminoguanidine is a nucleophilic hydrazine and its anti-AGE properties result from trapping of early glycation products such as carbonyl intermediate compounds. It has no effects on more advanced stages of glycation. Despite its potential effects in attenuating various diabetes- and age-related complications in animal models, its use in clinical practice is limited due to adverse effects in clinical trials with diabetic patients.108 In an in vitro skin aging model it could attenuate collagen glycation, however its effects against AGE-induced collagen modification in vivo have been contradictory.109–111 Studies on topical application of aminoguanidine in the skin are lacking.

    Pyridoxamine, a naturally occurring vitamin B6 isoform, seems to be another tool in the fight against AGEs. Pyridoxamine traps reactive carbonyl intermediates, scavenges ROS and in addition inhibits post-Amadori stages of AGEs formation.112 It has shown promising results in a phase II clinical trial against diabetic nephropathy.113 Oral intake of pyridoxamine resulted in potent inhibition of skin collagen CML formation in diabetic rats.111 However, its potential against skin aging remains to be shown.

    2. “AGE breakers”

    Chemical substances and enzymes able to recognize and break the Maillard reaction crosslinks have been identified. Such chemical AGE breakers are dimethyl-3-phenayl-thiazolium chloride (ALT-711), N-phenacylthiazolium and N-phenacyl-4,5-dimethylthiazolium.113 They have been developed to chemically break the prototypical Maillard reaction crosslink via a thiazolium structure.113 Promising results against cardiovascular complications in diabetes and aging have been reported, although their actual ability to cleave existing protein crosslinks in tissues has been questioned.114–117 In the rat ALT-711 showed some promising results on skin hydration.113

    Interference with intrinsic AGE-detoxifying enzymes like FAOXs, FN3K and the enzymatic system of Glo is another interesting strategy to remove AGEs, as enzymes recognize specific substrates and may be associated with fewer side effects.37,38,118 There are a lot of data supporting the significance of these enzyme systems in aging. As noted above decreased Glo I activity and increased accumulation of AGEs with age have been shown in many tissues and animals.37 Overexpression of Glo I significantly inhibits hyperglycemia-induced intracellular formation of AGEs in bovine aortic endothelial cells and in mouse mesangial cells by reduction of intracellular oxidative stress and apoptosis.119,120 A potential in vivo beneficial effect of Glo I against AGEs could be also shown in transgenic rats.121 Interestingly, it has been recently shown that Glo I is transcriptionally controlled by Nrf2, and that pharmacological Nrf2 activators increase Glo I mRNA and protein levels as well as its activity.122 The pharmacological induction of such enzymes could represent a novel future strategy against AGEs. Fructosamine phosphokinases are relatively new enzymes and currently under investigation, and until now no inductors or activators of their expression have been found.40 FAOXs on the other hand are not expressed in mammals, and their potential use in humans by enzymatic engineering remains to be discovered.39

    3. Nutriceuticals

    Since oxidation steps are crucially involved in formation of many AGEs, substances with antioxidative or metal chelating properties, may also have antiglycating activities.123 Thus, a lot of interest has been directed to nutrients and vitamins, so called “nutriceuticals,” as natural tools against AGEs.106,124

    Accordingly, an increasing list of natural antioxidants and chelating agents such as ascorbic acid, α-tocopherol, niacinamide, pyridoxal, sodium selenite, selenium yeast, trolox, rivoflavin, zink and manganese has been shown to inhibit glycation of albumin in vitro.125 Alpha-lipoic acid was able to reverse tail tendon collagen glycation in fructose-fed rats, an effect which was attributed to its endogenous antioxidant action, its ability to recycle ascorbic acid, α-tocopherol and GSH as well as to its positive influence on glucose uptake and glycaemia.126 Green tea, vitamins C and E and a combination of N-acetylcystein with taurine and oxerutin could inhibit skin collagen glycation in mice.124,127 Another compound, the green tea-derived polyphenol and flavonoid epigallocatechin-3-gallate revealed also promising in vitro effects by antagonizing AGE-induced proinflammatory changes.128 In healthy human subjects, supplementation of vitamin C significantly decreased serum protein glycation.129

    Many spices and herbs were shown to inhibit glycation of albumin in vitro, among them ginger, cinnamon, cloves, marjoram, rosemary and tarragon.130 Their protective effects correlated with their phenolic content. Recently, in vivo beneficial effects of some of these compounds were shown in zebrafish.131

    Other promising compounds include blueberry extract and naturally occurring flavonoids, such as luteolin, quercetin and rutin, which can inhibit various stages of AGE formation.132,133 Recently, blueberry extract, an AGE-inhibitor and C-xyloside, a glycosaminoglycan synthesis stimulator, were tested for 12 weeks in female diabetic subjects. This treatment resulted in significant improvement of skin firmness, wrinkles and hydration although it failed to show a significant decrease in the cutaneous content of AGEs.132

    4. Caloric restriction and dietary measures

    As nutrition is an important factor in skin aging, dietary caloric restriction may be effective in preventing accumulation of AGEs in the human body. In mice restriction of caloric intake increases lifespan and delays many age-related dysfunctions by altering stress response and influencing the expression of various metabolic and biosynthetic genes.134 Dietary restriction could significantly decrease the levels of AGEs in rat and mice skin collagen.135,136 Skin collagen glycation and glycoxidation inversely correlated with lifespan whereas caloric restriction led to decreased accumulation of AGEs and increased lifespan.137Dietary restriction may not be a pragmatic option in humans; however a restriction in intake of dietary “glycotoxins” may be more feasible. As outlined above these dietary glycotoxins derive from nutrition. In humans dietary glycotoxins significantly increase concentrations of systemic inflammatory mediators like TNFα, interleukin (IL)-6 and C-reactive protein and are thus considered as diabetogenic, nephrotoxic and proatherogenic.59,138,139 Dietary intake of AGEs correlates with serum AGEs and can induce systemic oxidative stress, increase RAGE expression, decrease antioxidant levels and shorten lifespan in mice.54 A diet with a low content in AGEs could reduce circulating AGEs and inflammatory biomarkers in patients with diabetes and renal failure thus seeming to be an important supportive therapy in diabetes.140,141 In mice low dietary AGEs had beneficial effects in wound healing and other diabetes mellitus-associated pathologies.142 There are no studies investigating the effects of AGE-poor diets on skin aging in humans. However, it has been shown that skin collagen glycation positively correlates with blood glucose levels in diabetes and that intensive treatment can reduce the levels of skin glycation, implicating that a diet low in AGEs may have a beneficial effect on skin glycation.143,144

    5. Targeting RAGE

    Another potential strategy against excessive accumulation of AGEs could be the antagonism of RAGE.145Possible approaches include gene knock-down of RAGE by siRNA or anti-sense and antagonism of RAGE with putative small molecular inhibitors against RAGE-induced signaling.50,145 Promising effects in various systems have been shown in vitro and in vivo with neutralizing anti-RAGE antibodies.41 Since serum concentrations of sRAGE negatively correlate with AGE-induced pathologies, neutralization of AGEs by these decoy receptors of RAGE may be considered as another potential anti-AGE strategy. Potential protective effects of sRAGE have been shown in various diabetes and inflammatory models.41,44,45,146Interestingly, sRAGE could also attenuate impaired wound healing in diabetic mice. Therefore, studies will be needed to investigate an analogous effect on skin aging.147

    6. Others

    Molecular chaperones like carnosine have lately shown promise in improving skin appearance in various studies at least in part by reducing the amounts of skin AGEs.148–150

    Conclusion

    There is ample evidence that AGEs play an important role in skin aging. There are also numerous studies investigating potential substances against excessive accumulation of AGEs in tissues. Some of these studies have already shown protective effects against diabetic complications. As controlled human studies investigating the effects of these anti-AGE strategies against skin aging are largely missing, this is a hot field for future research.

    SCIENTIFIC STUDIES:

    1. A new model of AGE -related macular degeneration induced by advanced glycation end product s
    2. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE )-related disorders
    3. A preliminary report on AGE -related elevations of saliva advanced glycation endproducts (AGE s) and arNOX
    4. A review on advanced glycation end–products (AGE ) and their role in diabetes mellitus
    5. A survey of fluorescence derived from advanced glycation end product s in the skin of Japanese: differences with AGE and measurement location
    6. ABCA4, 3–4 advanced glycation endproduct (AGE ) formation and AMD, 35–37 AGE -related macular degeneration (AMD)
    7. Accumulation of advanced glycation end product s of the Maillard reaction with AGE in human hippocampal neurons
    8. Actions of advanced glycation endproducts (AGE ) on coronary artery vascular smooth muscle cells
    9. Adhesion, monocytic cells to endothelial cells, 53-54 advanced glycation end product s (AGE ) diabetic complications, 24
    10. advanced glycation end (AGE ) product modification of laminin downregulates Kir4. 1 in retinal Müller cells
    11. advanced glycation end product (AGE ) accumulation in the skin is associated with depression: the maastricht study
    12. advanced glycation end product (AGE ) accumulation on Bruch’s membrane: links to AGE -related RPE dysfunction
    13. advanced glycation end product (AGE ) inhibition as a possible pharmacotherapeutic strategy in the treatment of Alzheimer’s disease
    14. advanced glycation end product (AGE ) inhibitors and their therapeutic implications in diseases.
    15. advanced glycation end product (AGE ) modified proteins in tears of diabetic patients
    16. advanced glycation end product (AGE ) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor
    17. advanced glycation end product (AGE )-AGE receptor (RAGE ) system upregulated connexin43 expression in rat cardiomyocytes via PKC and Erk MAPK pathways
    18. advanced glycation end product (AGE )-induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis
    19. advanced glycation end product (AGE )-induced proliferation of HEL cells via receptor for AGE -related signal pathways
    20. advanced glycation end product (AGE )-Mediated Reactive Oxygen Species production in Cultured endothelial Cells is Dependent on NADPH Oxidase Activation.
    21. advanced glycation end product (AGE )-receptor for AGE (RAGE ) signaling and up-regulation of Egr-1 in hypoxic macrophAGE s
    22. advanced glycation end product (AGE )‐immunoreactive materials in chronic prurigo patients receiving a long‐standing haemodialysis
    23. advanced glycation end product (AGE )–mediated induction of tissue factor in cultured endothelial cells Is dependent on RAGE
    24. advanced glycation end product (AGE ), soluble receptor for AGE (sRAGE ) and inflammation in smokers and mild/moderate chronic obstructive pulmonary disease …
    25. advanced glycation end product (AGE ): Characterization of the products from the reaction between D‐glucose and serum albumin
    26. advanced glycation end product s (AGE ) and diabetes: cause, effect, or both?
    27. advanced glycation end product s (AGE ) and Receptor for AGE (RAGE ) in Patients with Active Tuberculosis
    28. advanced glycation end product s (AGE ) and receptor for AGE (RAGE ) in patients with active tuberculosis, and their relationship between food intake and …
    29. advanced glycation end product s (AGE ) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce …
    30. advanced glycation end product s (AGE ) and their receptor (RAGE ) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
    31. advanced glycation end product s (AGE ) enhance vascular endothelial growth factor (VEGF) production in promonocytic leukaemia THP-1 cells
    32. advanced glycation end product s (AGE ) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and …
    33. advanced glycation end product s (AGE ) potentiates cell death in p53 negative cells via upregulaion of NF‐kappa B and impairment of autophagy
    34. advanced glycation end product s (AGE ) potently induce autophagy through activation of RAF protein kinase and nuclear factor κB (NF-κB)
    35. advanced glycation end product s (AGE ) stimulate the expression of the receptor for AGE (RAGE ) in hepatic stellate cells but do not induce cell …
    36. advanced glycation end product s (AGE )-modified proteins and their potential relevance to atherosclerosis
    37. advanced glycation end product s (AGE s) and the soluble receptor for AGE (sRAGE ) in patients with type 1 diabetes and coeliac disease
    38. advanced glycation end product s (AGE s) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE -infused rats.
    39. advanced glycation end product s accelerate arteriosclerosis after renal transplantation through the AGE /RAGE /ILK pathway
    40. advanced glycation end product s and their receptor in AGE -related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential …
    41. advanced glycation end product s in AGE -related macular degeneration
    42. advanced glycation end product s Interfere with Gastric Smooth Muscle Contractile Marker Expression Via the AGE /RAGE /NF-ΚB Pathway
    43. advanced glycation end product s interfere with gastric smooth muscle contractile marker expression via the AGE /RAGE /NF-κB pathway
    44. advanced glycation end product s measured by AGE Reader in a group of patients with obesity
    45. advanced glycation end–product (AGE ) induces apoptosis in human retinal ARPE-19 cells via promoting mitochondrial dysfunction and activating the Fas-FasL …
    46. advanced glycation end–product (AGE )-albumin from activated macrophAGE is critical in human mesenchymal stem cells survival and post-ischemic …
    47. advanced glycation end–product (AGE )-damAGE d IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis
    48. advanced glycation end–product Inhibition With AlAGE brium Slows AGE -Related Large Vessel Arterial Stiffening in Healthy Elderly Humans
    49. advanced glycation end–products in AGE -Related Arterial Stiffening: Modulation by Sodium Nitrite
    50. advanced glycation end–products: a common pathway in diabetes and AGE -related erectile dysfunction
    51. advanced glycation endprocucts Is Involved in the Development of AGE -Associated Glomeruloselerosis through Growth Arrest Specific Gene 6.
    52. advanced glycation endproduct “AGE ” Accumulation in Elderly Hypertensive Canines: Correlation with Effects of AGE Crosslink Breaker
    53. advanced glycation endproduct (AGE )
    54. advanced glycation endproduct (AGE )
    55. advanced glycation endproduct (AGE ) accumulation and AGE receptor (RAGE ) up‐regulation contribute to the onset of diabetic cardiomyopathy
    56. advanced glycation endproduct (AGE ) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells
    57. advanced glycation endproduct (AGE ) receptor interactions on microvascular cells occur within the caveolae membrane system
    58. advanced glycation endproducts (AGE ) and their role in the pathogenesis of chronic complications of diabetes mellitus
    59. advanced glycation endproducts (AGE ) Inhibit Scavenger Receptor Class B Type I-Mediated Reverse Cholesterol Transport
    60. advanced glycation endproducts (AGE ) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA).
    61. advanced glycation endproducts (AGE ) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing an oxidant stress in the …
    62. advanced glycation endproducts accumulate in RPE lysosomal compartments and induce widespread alteration in gene expression: possible role in AGE -related …
    63. advanced glycation endproducts on Bruch’s Membrane Can Be Detected by Raman Microscopy and Correlate With Chronological AGE
    64. advanced glycation endproducts: a biomarker for AGE as an outcome predictor after cardiac surgery?
    65. advanced glycation endproducts: Biomarkers for AGE -related Macular Degeneration
    66. advanced glycation in diabetes, aging and AGE -related diseases: conclusions
    67. advanced glycation in diabetes, aging and AGE -related diseases: editorial and dedication
    68. advanced glycation–New AGE Focus for Diabetes
    69. advanced glycation: an important pathological event in diabetic and AGE related ocular disease
    70. advanced nonenzymatic glycation endproducts (AGE ): their relevance to aging and the pathogenesis of late diabetic complications.
    71. AG490, 546 AGE , advanced glycation end–products, 142 Aggresome, 93 Alcoholic hepatitis, 277
    72. AGE (advanced glycation end product s) receptors in AGE –related macular degeneration
    73. AGE and genetic determinants of variation of circulating levels of the receptor for advanced glycation end product s (RAGE ) in the general human population
    74. AGE dependent accumulation patterns of advanced glycation end product receptor (RAGE ) ligands and binding intensities between RAGE and its ligands …
    75. AGE -and diabetes-related nonenzymatic crosslinks in collAGE n fibrils: candidate amino acids involved in advanced glycation end–products
    76. AGE -and passAGE -dependent upregulation of fibroblast elastase-type endopeptidase activity. Role of advanced glycation endproducts, inhibition by fucose-and …
    77. AGE -and stAGE -dependent accumulation of advanced glycation end product s in intracellular deposits in normal and Alzheimer’s disease brains
    78. AGE -dependent accumulation of advanced glycation end–products in adult Drosophila melanogaster
    79. AGE -dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine
    80. AGE -dependent expression of advanced glycation end product receptor genes in the human heart
    81. AGE -related accumulation of advanced glycation end product s modifications reflect the vascular and cardiac function
    82. AGE -related accumulation of advanced glycation end–products-albumin, S100β, and the expressions of advanced glycation end product receptor differ in visceral and …
    83. AGE -related accumulation of the advanced glycation endproduct pentosidine in human articular cartilAGE aggrecan: the use of pentosidine levels as a quantitative …
    84. AGE -related changes in cells and tissues due to advanced glycation end product s (AGE s)
    85. AGE -related effects of advanced glycation end product s (AGE s) in bone matrix on osteoclastic resorption
    86. AGE -related increase in an advanced glycation end product in penile tissue
    87. AGE ‐related decrease in susceptibility of human articular cartilAGE to matrix metalloproteinase–mediated degradation: The role of advanced glycation end product s
    88. AGE ‐related expression, enzymatic solubility and modification with advanced glycation end‐products of fibrillar collAGE ns in mouse lung
    89. AGE nts that block advanced glycation end product (AGE )-RAGE (receptor for AGE s)-oxidative stress system: a novel therapeutic strategy for diabetic vascular …
    90. Agonism of GPR39 displays protective effects against advanced glycation end–product (AGE )-induced degradation of extracellular matrix in human SW1353 cells
    91. Altered serum glyceraldehyde-derived advanced glycation end product (AGE ) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia
    92. An advanced glycation end product (AGE )-receptor for AGE s (RAGE ) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein …
    93. An advanced glycation end product (AGE )-receptor for AGE s (RAGE ) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein …
    94. An advanced glycation end product (AGE )-receptor for AGE s (RAGE ) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein …
    95. An advanced glycation end product (AGE )-rich diet promotes Nε-carboxymethyl-lysine accumulation in the cardiac tissue and tendons of rats
    96. An advanced glycation endproduct (AGE )‐rich diet promotes accumulation of AGE s in Achilles tendon
    97. An advanced glycation endproduct cross-link breaker can reverse AGE -related increases in myocardial stiffness
    98. Analysis of advanced glycation end product s (AGE s) in dentine: useful for AGE estimation?
    99. Anti-tumorigenic effect of AGE -/diabetes-related advanced glycation end–products in lung carcinoma
    100. Atorvastatin inhibits advanced glycation end product s (AGE )-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation
    101. Benfotiamine Prevents Acute Vascular Dysfunction (AVD) Induced by Food advanced glycation endproducts (AGE ) in Patients with Type 2 Diabetes …
    102. CD36‐mediated endocytic uptake of advanced glycation end product s (AGE ) in mouse 3T3‐L1 and human subcutaneous adipocytes
    103. CD36, serves as a receptor for advanced glycation endproducts (AGE )
    104. Changes in biomechanical properties, composition of collAGE n and elastin, and advanced glycation endproducts of the rat aorta in relation to AGE
    105. CHRONIC ADMINISTRATION OF ALBUMIN MODIFIED BY advanced glycation (AGE ) INDUCES EXPRESSION OF PRO-FIBROTIC, PRO-APOPTOTIC AND …
    106. Circulating levels of advanced glycation end product s (AGE ) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) …
    107. Circulating levels of soluble Receptor for advanced glycation end–products (sRAGE ) decrease with aging and may predict AGE -related cardiac remodeling
    108. Comparative suppressing effects of black and green teas on the formation of advanced glycation end product s (AGE s) and AGE -induced oxidative stress
    109. Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE ) and haemoglobin A1c for the assessment of diabetic control
    110. Comparison of in vitro protein modification with advanced glycation endproduct (AGE ) precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using …
    111. Confocal Raman microscopy can quantify advanced glycation end product (AGE ) modifications in Bruch’s membrane leading to accurate, nondestructive prediction of …
    112. Correlative study of advanced glycation end product s (AGE ) and diabetic skin with microangiopathy
    113. Curcumin eliminates the inhibitory effect of advanced glycation end–products (AGE s) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro
    114. Cytotoxicity of acetaldehyde‐derived advanced glycation end‐products (AA‐AGE ) in alcoholic‐induced neuronal degeneration
    115. Demonstration of the cytotoxic effect of advanced glycation endproducts (AGE -s)
    116. Deposition of advanced glycation end product s (AGE ) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
    117. Depression of progenitor cell function by advanced glycation endproducts (AGE s): potential relevance for impaired angiogenesis in advanced AGE and diabetes
    118. Detection of autoantibodies against advanced glycation endproducts and AGE -immune complexes in serum of patients with diabetes mellitus
    119. Detection of galectin-3 and localization of advanced glycation end product s (AGE ) in human chronic skin wounds
    120. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end product s (AGE ) in serum of diabetic patients
    121. Diabetic erythrocytes bearing advanced glycation end product s (AGE ) bind to the receptor for AGE and increase vascular permeability
    122. Diabetic kidney disease: a role for advanced glycation end–product receptor 1 (AGE -R1)?
    123. Diet-Derived advanced glycation endproducts (dAGE ) Contribute to Circulating AGE Levels, Induce Inflammation and Are Associated with Higher Fasting …
    124. Dietary advanced glycation end product s have sex‐and AGE ‐dependent effects on vertebral bone microstructure and mechanical function in mice
    125. Dietary advanced glycation endproducts (AGE ) Impaired The endothelial Function In Healthy Eutrophic In Aging Process
    126. Differences in the modulating potential of advanced glycation end product (AGE ) peptides versus AGE proteins
    127. Effect of advanced glycation end‐products (AGE ) lowering drug ALT‐711 on biochemical, vascular, and bone parameters in a rat model of CKD‐MBD
    128. Effect of AGE and menopause on serum concentrations of pentosidine, an advanced glycation end product
    129. Effect of the AGE -breaker alAGE brium on plasma and tissue advanced glycation end–products and sRAGE
    130. Effect of γ-Glutamyl Cysteine Derivatives from Garlic on advanced glycation end–product (AGE ) Formation during Food Processing
    131. EFFECTS OF A DIET RICH IN advanced glycation end product S (AGE ) ON ALZHEIMER’S-LIKE BEHAVIOR AND NEUROPATHOLOGY
    132. Effects of advanced glycation end–products (AGE s) on retinal pigment epithelial (RPE) cells lysosomal function: implications for AGE -related macular degeneration …
    133. Effects of advanced glycation endproducts (AGE ) on Rat Glomerular Epithelial Cells (GEC): Roles of Reactive Oxygen Species (ROS)
    134. Effects of carvedilol and metoprolol on plasma advanced glycation end product s (AGE ) and advanced oxidation protein products (AOPP) in patients with chronic heart …
    135. endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end product s (AGE )-mediated inhibition of endothelial nitric oxide …
    136. Enhanced binding of advanced glycation endproducts (AGE ) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer’s disease
    137. Enhanced plasma levels of advanced glycation end product s (AGE ) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after …
    138. Estimation of AGE of human cadavers by immunohistochemical assessment of advanced glycation end product s in the hippocampus
    139. Exercise training initiated in late middle AGE attenuates cardiac fibrosis and advanced glycation end–product accumulation in senescent rats
    140. Exposure of Retinal Pigment Epithelium (RPE) to advanced glycation endproduct (AGE )–Modified Substrate in vitro Alters RPE Lysosomal Capacity and Leads to …
    141. Exposures of advanced glycation end product s (AGE ) to Bovine Retinal Capillary endothelial Cell (BREC) and Assess Their Glucose Uptake
    142. Expression of advanced glycation end product (AGE ) Receptors in Corneal endothelial Cells
    143. Food advanced glycation endproducts (AGE ) Acutely Impair endothelium-Dependent Vasodilatation in Patients with Type 2 Diabetes Mellitus (T2DM)
    144. Food advanced glycation endproducts (AGE ) Acutely Induce Postprandial Impairment of Microvascular Function in Patients with Type 2 Diabetes Mellitus (T2DM), an …
    145. Food advanced glycation endproducts (AGE ) Induce Expression of P-Selectin in Platelets from Diabetics and Nondiabetic Subjects
    146. Formation of advanced glycation end (AGE ) products in diabetes: Prevention by pyruvate and a-keto glutarate
    147. Formation of advanced glycation end product s (AGE ) in vitro and their impact on adipocyte function
    148. FRS-078 Serum Pentosidine, an advanced glycation end product (AGE ), is a Risk Factor for Heart Failure (Clinical Heart Failure, Diagnosis and …
    149. Fundus Autofluorescence in a Rabbit Model of AGE -Related Macular Degeneration Induced by advanced glycation end product Microspheres as Imitation Lipofuscin
    150. Galectin–3 mediates advanced glycation endproduct (AGE )–induced breakdown of the blood–retinal barrier
    151. Gene Polymorphisms of the Receptor for advanced glycation end product s and Its Role in the AGE -RAGE Pathway and Inflammation
    152. Generation of active oxygen species from advanced glycation end–products (AGE ) under ultraviolet light A (UVA) irradiation
    153. Global proteomic analysis of advanced glycation end product s in the Arabidopsis proteome provides evidence for AGE -related glycation hot spots
    154. High serum level of pentosidine, an advanced glycation end product (AGE ), is a risk factor of patients with heart failure
    155. High Serum Level of Pentosidine, an advanced glycation end product (AGE ), is a Risk Factor of Patients with Heart Failure
    156. Hypoxia‐induced increases in glucose uptake do not cause oxidative injury or advanced glycation end‐product (AGE ) formation in vascular endothelial cells
    157. Identification of (−)-epigallocatechin (EGC) as a methylglyoxal (MGO)-trapping AGE nt and thereby as an inhibitor of advanced glycation end product (AGE ) …
    158. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end product s (AGE ): a new member of the AGE -receptor complex
    159. Immunohistochemical study of human advanced glycation end–products (AGE ) and growth factors in cardiac tissues of patients on maintenance dialysis and with …
    160. Impairment of glyoxalase-1, an advanced glycation end–product detoxifying enzyme, induced by inflammation in AGE -related osteoarthritis
    161. Importance of advanced glycation end product s–AGE products
    162. Improved methods for quantifying plasma protein advanced glycation end product s as biomarkers for AGE -related macular degeneration
    163. Increase in the advanced glycation end product pentosidine in Bruch’s membrane with AGE .
    164. Induction of AGE -related Macular Degeneration (AMD) by advanced glycation end (AGE ) products and S100B
    165. Influence of advanced glycation end–products and AGE -inhibitors on nucleation-dependent polymerization of β-amyloid peptide
    166. Inhibition of advanced glycation endproduct (AGE ) Formation by the Alcohol Metabolite Acetaldehyde: Role in the” French Paradox”
    167. Inhibition of advanced glycation endproduct (AGE ) rescues against streptozotocin-induced diabetic cardiomyopathy: role of autophagy and ER stress
    168. Interactions between advanced glycation end–products (AGE ) and their receptors in the development and progression of diabetic nephropathy-are these receptors …
    169. Involvement of aldosterone-mineralocorticoid receptor system in advanced glycation end product (AGE )-elicited plasminogen activator inhibitor-1 (PAI-1) expression …
    170. Involvement of the insulin-like growth factor (IGF) system in the advanced glycation endproduct (AGE )-induced modulation of osteoblast development
    171. Irbesartan inhibits advanced glycation end product (AGE )-induced proximal tubular cell injury in vitro by suppressing receptor for AGE s (RAGE ) expression
    172. Irbesartan inhibits advanced glycation end product (AGE )-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular …
    173. Knockout of receptor for advanced glycation end‐products attenuates AGE ‐related renal lesions
    174. Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end product s (AGE ) 
    175. Localization of identified advanced glycation end‐product structures, Nε=(carboxymethyl) lysine and pentosidine, in AGE ‐related inclusions in human brains
    176. Low‐Molecular Weight advanced glycation end product s: Markers of Tissue AGE Accumulation and More?
    177. Lowering of dietary advanced glycation endproducts (AGE ) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice
    178. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse AGE -mediated cellular effects in vitro: a potential AGE …
    179. Mechanistic targeting of advanced glycation end–products in AGE -related diseases
    180. Metabolic and renal effects of dietary advanced glycation end product s in pregnant rats–A Pilot Study Short title: AGE -rich diet in pregnancy
    181. Metabolism Of advanced glycation end product s (AGE s) By The Polyol Pathway Enzyme-Aldose Reductase Decreases AGE Accumulation In Diabetes
    182. Methods for studying the binding of advanced glycated proteins to receptors for advanced glycation endproducts (AGE receptors)
    183. Methylglyoxal induced advanced glycation end product s (AGE )/receptor for AGE (RAGE )-mediated angiogenic impairment in bone marrow-derived endothelial …
    184. Molecular basis of maillard amide-advanced glycation end product (AGE ) formation in vivo
    185. Molecular characterization of a mouse genomic element mobilized by advanced glycation endproduct modified-DNA (AGE -DNA)
    186. MON-PO333: Are advanced glycation end product (AGE ) Levels Associated with Frailty in Dutch Older Adults?
    187. Myricetin inhibits advanced glycation end product (AGE )-induced migration of retinal pericytes through phosphorylation of ERK1/2, FAK-1, and paxillin in vitro and in …
    188. N-butanol extracts of Morinda citrifolia suppress advanced glycation end product s (AGE )-induced inflammatory reactions in endothelial cells through its anti …
    189. N-Terminal 2, 3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE ) formation
    190. N‐Phenacylthiazolium Bromide Inhibits the advanced glycation end product (AGE )–AGE Receptor Axis to Modulate Experimental Periodontitis in Rats
    191. N. epsilon.-(Carboxymethyl) lysine is a dominant advanced glycation end product (AGE ) antigen in tissue proteins
    192. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE )-exposed fibroblasts via …
    193. Nucleophilic Compounds Block advanced glycation end product (AGE ) Formation From Ascorbic Acid in the hSVCT2-enA Transgenic Mouse Model of Lenticular …
    194. OE-091 Involvement of Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) in advanced glycation end product s (AGE )/RAGE -Signaling Pathways …
    195. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damAGE in advanced glycation end product (AGE )-injected …
    196. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE )-related disorders
    197. Oral advanced glycation endproducts (AGE s) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1
    198. Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGE s) in aging and AGE -related diseases
    199. OxiSelect™ advanced glycation end product (AGE ) ELISA Kit
    200. P-456 advanced glycation end–products (AGE ) are novel markers to predict poor IVF outcomes independently of AGE and FSH: novel therapy for poor responders
    201. P1-421: The role of advanced glycation endproduct (AGE ) receptors in the pathogenesis of Alzheimer’s disease
    202. P10 Localization of advanced glycation end product s (AGE ) in actinic elastosis
    203. P35 SOLUBLE RECEPTOR FOR advanced glycation end–productS AND AGE -DEPendENT ARTERIAL STIFFENING IN GENERAL POPULATION …
    204. P4760 AGE -related changes in the biomechanics of left ventricular twist are associated with accumulation of advanced glycation end–products and replicative …
    205. Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: implications for AGE -related degenerative diseases of the eye
    206. Pharmacological blockade of the receptor for advanced glycation endproducts (RAGE ) improves AGE -related endothelial dysfunction in rats
    207. Phase I clinical studies of the advanced glycation end–product (AGE )-breaker TRC4186
    208. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE )-induced C-reactive protein expression in hepatoma cells by …
    209. Pigment epithelium-derived factor (PEDF) inhibits diabetes-or advanced glycation end product (AGE )-induced platelet CD40 ligand overexpression in rats
    210. Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced glycation end product s (AGE )-elicited retinal leukostasis
    211. Plasma advanced glycation end product s (AGE s), receptors for AGE s and their correlation with inflammatory markers in middle school-AGE children
    212. Plasma advanced glycation end product s (AGE s), receptors for AGE s and their correlation with inflammatory markers in middle school-AGE children
    213. Positive Correlation of Serum advanced glycation end product (AGE ) Levels with Thrombogenic Markers in Non-diabetic General Population (Preventive …
    214. POSSIBLE ROLE OF STATIN ON THE OXIDATIVE STRESS INDUCED BY advanced glycation end product (AGE ) IN VSMC OF DIABETIC …
    215. Potential clinical utility of advanced glycation end product cross-link breakers in AGE -and diabetes-associated disorders
    216. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE )-related disorders
    217. Prevention and reversible solubilization of advanced glycation and products (AGE ) by organic germanium compounds as derivatives of amino acids
    218. production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an advanced glycation end–product (AGE ), wi th Reduced Inter-Domain Motion.
    219. production of single-chain Fv antibodies specific for GA-Pyridine, an advanced glycation end–product (AGE ), with reduced inter-domain motion
    220. Proinflammatory signalling by receptor for advanced glycation end product s (RAGE ), an important mediator of retinal pigment epithelium (RPE) dysfunction and AGE …
    221. Protection against loss of innate defenses in adulthood by low advanced glycation end product s (AGE ) intake: role of the antiinflammatory AGE receptor-1
    222. Proteomic Analysis of advanced glycation end–product (AGE ) Modified Proteins in High Glucose-Exposed Retinal Müller Glia: Evidence for AGE -Mediated Cell …
    223. Proteomic Analysis of advanced glycation endproduct (AGE )-Modified Proteins in Müller Cells During High Glucose Exposure: Implications for Macroglial Dysfunction …
    224. PS 05-68 NO CROSS-SECTIONAL ASSOCIATION FOUND BETWEEN SKIN advanced glycation end product S (AGE ) AND ARTERIAL STIFFNESS IN A …
    225. Pyridoxamine, an inhibitor of advanced glycation end product (AGE ) formation ameliorates insulin resistance in obese, type 2 diabetic mice
    226. Reactive oxygen species (ROS) and advanced glycation end product s (AGE )-induced ERK5-SUMOylation antagonizes anti-inflammatory effect of shear stress in …
    227. Receptor for advanced glycation end product s (AGE s) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
    228. Receptor for advanced glycation end product s (RAGE )-expressing endothelial cells co-express AGE and S100 in human periapical granulomas
    229. Receptor for advanced glycation end product s and AGE -related macular degeneration
    230. Receptors for advanced glycation end–products (AGE )—expression by endothelial cells in non-diabetic uraemic patients
    231. Receptors for proteins modified by advanced glycation endproducts (AGE )—their functional role in atherosclerosis
    232. Reduced Pericyte Adhesion and Death on advanced glycation endproduct (AGE )–Modified Substrate
    233. Reduction of advanced glycation end‐product (AGE ) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of …
    234. Regulation of advanced glycation end product (AGE ) receptors and apoptosis by AGE s in osteoblast-like cells
    235. Regulation of advanced glycation end product (AGE )-receptor (RAGE ) system by PPAR-gamma agonists and its implication in cardiovascular disease
    236. Renoprotection is afforded by the advanced glycation end product (AGE ) cross-link breaker, ALT-711.
    237. Renoprotection of anti-hypertensive AGE nts is associated with inhibition of advanced glycation end product (AGE ) formation.
    238. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE )-injected rats.
    239. Role of advanced glycation end product (AGE )-induced receptor (RAGE ) expression in diabetic vascular complications
    240. Role of advanced glycation end product s (AGE ) and soluble receptor for AGE (sRAGE ) in vascular complications in diabetes
    241. Role of advanced glycation end product s (AGE ) in Health and Disease: An Overview
    242. Role of advanced glycation end product s (AGE ) in the development of diabetic microangiopathies and the beneficial effects of AGE inhibitors
    243. Role of advanced glycation end–products (AGE ) in late diabetic complications
    244. Serum advanced glycation end–products (AGE ) Are Elevated In Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction But Not …
    245. Serum advanced glycation end–products (AGE ) of Humans Before and After Consumption of an AGE -rich Meal
    246. Serum antibodies to advanced glycation endproducts (AGE ) and circulating AGE -immune complexes in NIDDM patients
    247. Serum Carboxymethyllysine, an advanced glycation end product , and AGE -Related Macular Degeneration: The AGE , Gene/Environment Susceptibility–Reykjavik …
    248. Serum Fluorescent advanced glycation end (F-AGE ) products in gestational diabetes patients
    249. Serum levels of advanced glycation end–products (AGE s) and the decoy soluble receptor for AGE s (sRAGE ) can identify non-alcoholic fatty liver disease in AGE -, sex …
    250. Serum levels of receptors for advanced glycation end product s in normal-weight and obese children born small and large for gestational AGE
    251. Sitagliptin ameliorates advanced glycation end–product (AGE )-induced degradation of extracellular matrix in human primary chondrocytes
    252. Skin advanced glycation end product s as a marker of reproductive AGE in women—a pilot study
    253. Soluble receptor for advanced glycation end product s (sRAGE ) is present at high concentrations in the lungs of children and varies with AGE and the pattern of lung …
    254. Soluble receptor for advanced glycation end–products independently influences individual AGE -dependent increase of arterial stiffness
    255. Solution Structure of the Variable-Type Domain of the Receptor for advanced glycation end product s: New Insight into AGE −RAGE Interaction,
    256. Study of an unusual advanced glycation end–product (AGE ) derived from glyoxal using mass spectrometry
    257. Targeting the AGE ‐RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end‐product content
    258. Telmisartan blocks advanced glycation end product (AGE )-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of …
    259. Telmisartan inhibits advanced glycation end product s (AGE s)-elicited endothelial cell injury by suppressing AGE receptor (RAGE ) expression via peroxisome …
    260. Th-P15: 106 advanced glycation end product s (AGE ), in contrast to OXLDL, do not stimulate macrophAGE gene expression VIA CD36
    261. The anti-ALS drug riluzole attenuates MCP-1 by high glucose, advanced glycation end product (AGE ) or TNF-α in cultured human retinal pericytes
    262. The association between variants of receptor for advanced glycation end product s (RAGE ) gene polymorphisms and AGE -related macular degeneration
    263. The clinical relevance of advanced glycation endproducts (AGE ) and recent developments in pharmaceutics to reduce AGE accumulation
    264. The Contribution of advanced glycation end product (AGE ) accumulation to the decline in motor function
    265. The Dimerisation of the Receptor for advanced glycation end–products (RAGE ) Is Essential for AGE -Induced Signaling in Diabetic Retinopathy
    266. The effect of advanced glycation end product s (AGE ) breaker, alAGE brium on the cardiac structural and functional change in type I diabetic rat model
    267. The Effect of advanced glycation end product s (AGE ) Breaker, AlAGE brium on the Cardiac Structural and Functional Change in Type I Diabetic Rat Model
    268. The Effects of advanced glycation end product s (AGE s) on endothelial Cell Nitric Oxide Synthase and Tumor Necrosis Factor‐α Expression Are AGE …
    269. The effekt of AGE difference on the serum level of advanced glycation end product s in patients with post infarction heart failure.
    270. The inhibition of advanced glycation end product s by carnosine and other natural dipeptides to reduce diabetic and AGE ‐related complications
    271. The protective effects of bexarotene against advanced glycation end–product (AGE )-induced degradation of articular extracellular matrix (ECM)
    272. The receptor for advanced glycation end product s (RAGE ) is a central mediator of the interaction of AGE -beta2microglobulin with human mononuclear phagocytes via …
    273. The relationship of glycaemic level to advanced glycation end–product (AGE ) accumulation and retinal pathology in the spontaneous diabetic hamster
    274. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE )-related disorders
    275. To AGE or not to AGE . The effect of physical activity and advanced glycation end–products (AGE s) on the vasculature in older individuals
    276. Treatment With Nitric Oxide (NO) Donors or Pioglitazone Improves CD34+ Cell Dynamics on advanced glycation end product (AGE ) Modified Basement Membrane
    277. Type IV collAGE n is transcriptionally regulated by Smad1 under advanced glycation end product (AGE ) stimulation
    278. Vitamin D attenuates human gingival fibroblast inflammatory cytokine production following advanced glycation end product interaction with receptors for AGE
    279. … -5, blocks advanced glycation end product (AGE )-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE …
    280. … -bis (methyl) carbamate from Cortex Mori on advanced glycation end product -induced endothelial dysfunction: Via inhibiting AGE formation or blocking AGE s–RAGE …
    281. … -like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE )-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE …
    282. … , a calcium channel blocker, inhibits advanced glycation end product (AGE )-elicited mesangial cell damAGE by suppressing AGE receptor (RAGE ) expression via …
    283. … (RAS) Inhibits Increased Matrix Metalloproteinase-9 Expression and Apoptosis Induced by advanced glycation end product s (AGE ) and Attenuates Receptor for AGE …
    284. … ADP-R, ADP receptor BBB, blood brain barrier AD-R, adenosine receptor BBI, Bowman–Birk serine protease inhibitor AGE , advanced glycation endproduct BB-R …
    285. … And Extracellular Soluble Receptor For advanced glycation end product s (esRAGE ) In Aqueous Humor Of Patients With AGE -related Macular Degeneration
    286. … by advanced glycation end product s increases the stiffness of the collAGE n network in human articular cartilAGE : a possible mechanism through which AGE is a risk …
    287. … Flavonol Glucosides Derived from Cherry Blossom Flowers on the production of advanced glycation end product s (AGE s) and AGE ‐induced Fibroblast Apoptosis
    288. … herbal medicines Padma 28 and Padma Circosan inhibit the formation of advanced glycation endproducts (AGE ) and advanced oxidation protein products …
    289. … in proteins modified with advanced glycation end product s (AGE s): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins
    290. … of a novel radical trapping and carbonyl group trapping anti-AGE AGE nt: a pyridoxamine analogue for inhibiting advanced glycation (AGE ) and lipoxidation (ALE) end …
    291. … of advanced glycation end–products (AGE ) are associated with poor outcomes in IVF/ICSI: a possible novel therapy for poor responders by decreasing AGE  
    292. … of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE …
    293. … of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE )–receptor for AGE (RAGE ) axis and …
    294. … of Human Serum Albumin HSA advanced glycation end product AGE and DNA AGE in Experimental Animals Profile of Anti HSA AGE and Anti DNA AGE …
    295. … Reaction by Organic Germanium Compounds. Molecular Mechanism on the Prevention and Reversible Solubilization of advanced glycation endproducts (AGE )
    296. … receptor for advanced glycation end product (AGE ) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE …
    297. … skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE ) pentosidine as an indirect indicator of AGE content in human …
    298. … substances in tail tendon collAGE n of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced glycation endproduct (AGE ) …
    299. 196 Strategies for Inhibiting advanced glycation endproduct (AGE ) Induced Vascular Calcification in a Smooth Muscle Cell Culture Model
    300. 2215-PUB: Serum Levels of the advanced glycation end product (AGE ) Pentosidine Do Not Correlate with the Extent of Coronary Artery Disease Assessed by …
    301. Inhibitory activity of advanced glycation endproducts (AGE) formation of edible plants for development of anti-wrinkle ingredients
    302. The role of hyperglycemia in skin wrinkle formation: Mediation of advanced glycation end-products
    303. Glycation stress and photo-aging in skin
    304. Advanced glycation end products: key players in skin aging?
    305. Innovative cosmeceuticals: sirtuin activators and anti-glycation compounds
    Share
    0
    INTERSTELLAR BLEND
    INTERSTELLAR BLEND

    Related posts

    October 6, 2020

    PPARY2


    Read more
    September 16, 2020

    NMDA & ANXIETY & DEPRESSION


    Read more
    September 16, 2020

    INFECTOBESITY


    Read more

    Comments are closed.

    Recent Posts

    • PPARY2
    • NMDA & ANXIETY & DEPRESSION
    • INFECTOBESITY
    • Anti-Acne effect of Flavonoids and Polyphenols
    • NOOTROPICS
    © 2021 Interstellar Blends | Activate Your Super Powers!. © 2019 Interstellar Blends | Activate Your Super Powers!. All Rights Reserved.

    Mandatory FDA Disclaimer
    Privacy Policy
    Terms and Conditions
    Have Questions?
    Contact Gavin Robert McGowen Here

    Join the following facebook groups to learn more:
    Ultimate Weightloss Challenge , Dry Fasting, Longevity Agents , Interstellar Blend Seven Sages, The Infinitely Postive, THE INTERSTELLAR BLEND CHALLENGE: Fluid Restricted Fasting w/ Superherbs

    Love this Website? Contact David Rodriguez to build you one!